What do systematic reviews say?

Sildenafil vs placebo

Sildenafil may leads to lower all‐cause mortality compared with placebo (low certainty).

• Sildenafil for pulmonary hypertension in neonates 2017 · Cochrane Headline outcomes only
  RR 0.2 [0.07, 0.56]
  3 studies · 77 participants
  Low

Sildenafil vs active control

It is very uncertain whether sildenafil changes all‐cause mortality compared with active control (very low certainty).

• Sildenafil for pulmonary hypertension in neonates 2017 · Cochrane Headline outcomes only
  RR 0.55 [0.05, 5.75]
  1 study · 65 participants
  Very low

Sildenafil plus iNO vs placebo plus iNO

Sildenafil plus iNO showed no clear difference in all‐cause mortality compared with placebo plus iNO (low certainty).

• Sildenafil for pulmonary hypertension in neonates 2017 · Cochrane Headline outcomes only
  RR 1.27 [0.26, 6.28]
  1 study · 24 participants
  Low

Sildenafil vs Placebo or no active treatment

Sildenafil citrate showed no clear difference in all‐cause mortality compared with placebo or no therapy (moderate certainty).

• Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
  RR 1.01 [0.8, 1.27]
  5 studies · 516 participants
  Moderate

Sildenafil vs IV nitroglycerin

• Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 23 participants
  Low